Research programme: anti-PAD4 antibodies - Pharma Foods International
Alternative Names: Anti-PAD4 mAb - Pharma Foods InternationalLatest Information Update: 28 Dec 2022
At a glance
- Originator Pharma Foods International
- Class Antirheumatics; Monoclonal antibodies
- Mechanism of Action Peptidylarginine deiminase type IV modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for research development in Rheumatoid-arthritis in Japan (Parenteral)
- 02 Nov 2018 Research programme: anti-PAD4 antibodies - Pharma Foods International is available for licensing as of 02 Nov 2018. https://www.pharmafoods.co.jp
- 02 Nov 2018 Pharma Foods International has patent protection for anti-PAD4 antibodies in Japan and has patents pending in USA, Europe